TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15220015

Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate (newly developed formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Amlodipine besylate (conventional formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 11558859

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg and 10 mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Ezetimibe (all doses)
Number of subjects: 432
Study: 9604858

Group type: EXPERIMENTAL
Intervention: Untreated coffee (150 ml)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Specially treated coffee (150 ml)
Number of subjects: 4
Study: 7786108

Group type: EXPERIMENTAL
Intervention: Short duration balloon inflation (3 or 4 successive inflations, each ≤ 1 min, total duration ≤ 3 min)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Long duration balloon inflation (3 to 5 inflations, each of 4 to 5 minutes, total duration ≥ 12 min)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Short duration balloon inflation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Long duration balloon inflation
Number of subjects: 224
Study: 3540137

Group type: EXPERIMENTAL
Intervention: Aspergillus fumigatus antigen radioimmunoassay (RIA)
Number of subjects: 79
Study: 30829117

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 72
Study: 29667557

Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic Acid) 500 mg orally twice daily for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-treated group (control)
Number of subjects: 10
Study: 28513786

Group type: EXPERIMENTAL
Intervention: Composite resin (CR) sealants
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) sealants
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Modified retention assessment criterion
Number of subjects: 123

Group type: COMPARATOR
Intervention: Traditional retention assessment criterion
Number of subjects: 123
Study: 25646254

Group type: EXPERIMENTAL
Intervention: Daily 4% chlorhexidine umbilical cord wash
Number of subjects: 39679

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 39679
Study: 23617089

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate (CP) 1.2%‐benzoyl peroxide (BPO) 2.5% gel
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Clindamycin phosphate (CP) 1.2%
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Benzoyl peroxide (BPO) 2.5%
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1755
Study: 21722003

Group type: EXPERIMENTAL
Intervention: stage-matched intervention
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: stage-mismatched intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: control treatment
Number of subjects: 326
Study: 19539253

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2797

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2797

Group type: EXPERIMENTAL
Intervention: Non-target lesion target vessel revascularization (TVR)
Number of subjects: 2797

Group type: EXPERIMENTAL
Intervention: Other major adverse events (including death, myocardial infarction, and stent thrombosis)
Number of subjects: 2797
Study: 16448279

Group type: EXPERIMENTAL
Intervention: Pumice before SEP application
Number of subjects: 30

Group type: COMPARATOR
Intervention: No pumice before SEP application
Number of subjects: 30
Study: 14693012

Group type: EXPERIMENTAL
Intervention: Various drinks intended to alleviate sleepiness
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nontreatment control conditions
Number of subjects: 38
Study: 10775629

Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homologous and heterologous antigens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Particular immunogen
Number of subjects: 0
Study: 9365092

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both treatment groups (oral prednisolone and intramuscular methylprednisolone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initial ESR
Number of subjects: 50
Study: 1530019

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 gm intravenous bolus)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4059295

Group type: EXPERIMENTAL
Intervention: 1.0 g triletide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5 g triletide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.0 g triletide
Number of subjects: 30
Study: 31743933

Group type: EXPERIMENTAL
Intervention: PneumRx endobronchial coil system
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard-of-Care Medical Management
Number of subjects: 210
Study: 28763309

Group type: EXPERIMENTAL
Intervention: Usual site VTE group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Unusual site VTE group
Number of subjects: 165
Study: 27207923

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Number of subjects: 40
Study: 24946635

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Western medication (tamsulosin hydrochloride 0.2 mg once daily, indometacin 75 mg once daily)
Number of subjects: 70
Study: 22325459

Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20849659

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17544361

Group type: EXPERIMENTAL
Intervention: Control-based coping strategies (distraction and cognitive restructuring)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Acceptance-based strategies (experiential acceptance and defusion techniques)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 98
Study: 15911734

Group type: COMPARATOR
Intervention: Sinus rhythm control
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation presence at stroke event
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Primary intraparenchymal hemorrhage
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Subdural or subarachnoid hemorrhage
Number of subjects: 4060
Study: 11777710

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOLs (AcrySof, AR40)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOLs (MemoryLens, Hydroview)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Silicone IOLs (CeeOn 920, CeeOn 911A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOLs (Hydroview, MemoryLens)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hydrophobic IOL groups
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sharp-edged optic IOLs (CeeOn 911A, AcrySof)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AR40 lens
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Postoperative cell count at 1 year
Number of subjects: 180
Study: 9449392

Group type: EXPERIMENTAL
Intervention: Essential hypertension
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 42
Study: 7653442

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg oral administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (identical to nicorandil)
Number of subjects: 10
Study: 2572631

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4%
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Glycol-poly-siloxane gel
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bland liquid soap
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sensitive-skin group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nasal carriers of MRSA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Weekly MRSA colonization rate in neonates
Number of subjects: 56
Study: 791971

Group type: EXPERIMENTAL
Intervention: Chlorhexidine paste used for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental paste used for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 0
Study: 31307434

Group type: EXPERIMENTAL
Intervention: CHIP lifestyle intervention programme (12 weeks) followed by 9 months of monthly follow-up appointments
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual ongoing diabetes care
Number of subjects: 150
Study: 28195844

Group type: EXPERIMENTAL
Intervention: 660 nm red LEDs
Number of subjects: 52

Group type: COMPARATOR
Intervention: 411 to 777 nm white LEDs
Number of subjects: 52
Study: 24664189

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: NND compliance
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 147
Study: 23318311

Group type: EXPERIMENTAL
Intervention: Selective testing (D-dimer testing for outpatients with low or moderate clinical pretest probability (C-PTP) and venous ultrasonography without D-dimer testing for high C-PTP and inpatients)
Number of subjects: 1723

Group type: COMPARATOR
Intervention: Uniform testing (D-dimer testing for all participants)
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Selective testing
Number of subjects: 1723
Study: 21682578

Group type: COMPARATOR
Intervention: Sun protection advice via letter
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Sun protection advice via personal GP consultation (Group 2)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Sun protection advice via personal GP consultation with phototest (Group 3)
Number of subjects: 316
Study: 19467051

Group type: EXPERIMENTAL
Intervention: Point vibration - ultrasonic vibration applied to the core surface for 5 s on each face, totaling 25 s
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternate vibration - intermittent application of ultrasonic vibration for 10 s to the labial and lingual surfaces, 10 s to the mesial and distal surfaces, and 5 s to the incisal surface, totaling 25 s
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 1 - core with 5 mm diameter/height and post diameter of 1.3 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 - core with the same diameter as the post (1.3 mm) and height of 5 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 3 - core with the same diameter as the post (1.3 mm) and height of 3 mm
Number of subjects: 60
Study: 16522295

Group type: EXPERIMENTAL
Intervention: Intensive stop‐smoking intervention six to eight weeks before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 15141412

Group type: EXPERIMENTAL
Intervention: Pump-assisted feeding (G1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gravity-controlled feeding (G2)
Number of subjects: 100
Study: 10674470

Group type: COMPARATOR
Intervention: Pre-operative serum Ig levels in brain tumours and LDDs
Number of subjects: 227

Group type: COMPARATOR
Intervention: Pre-operative serum IgG levels
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-operative serum IgA levels in patients with acoustic neurinoma
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-operative serum IgM levels in patients with acoustic neurinoma
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-operative serum IgG, IgA, and IgM levels in patients with meningioma
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-operative serum IgG and IgM levels in patients with glioma
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Post-operative serum IgA and IgM levels in patients with LDD
Number of subjects: 227
Study: 9308510

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (1.3 mg, 2 inhalations every 4 hours while awake for 1 week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (2 inhalations every 4 hours while awake for 1 week)
Number of subjects: 15
Study: 8345592

Group type: EXPERIMENTAL
Intervention: In situ extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ureteral manipulation before ESWL
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: In situ ESWL
Number of subjects: 110
Study: 3732093

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25‐50 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study: 30872075

Group type: EXPERIMENTAL
Intervention: High cutoff haemodialysis (HCO‐HD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HF‐HD)
Number of subjects: 90
Study: 30049811

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for PET- patients, 2 cycles followed by 2 more cycles after negative PET.
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) plus 3060-cGy involved-field RT for PET+ patients, 2 cycles after positive PET.
Number of subjects: 149
Study: 26716656

Group type: EXPERIMENTAL
Intervention: 5 g of encapsulated Cassia cinnamon bark (CASS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 g of encapsulated placebo (PLC)
Number of subjects: 10
Study: 24574351

Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ObeseND
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 22735863

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day for six months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (5 g/day of maltodextrin for six months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (CRE and PLA)
Number of subjects: 33
Study: 19262361

Group type: EXPERIMENTAL
Intervention: Optimal standard heart failure therapy
Number of subjects: 99
Study: 17638076

Group type: EXPERIMENTAL
Intervention: Proportional hazards mixed‐effects model (PHMM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized covariate residuals
Number of subjects: 0
Study: 12734897

Group type: EXPERIMENTAL
Intervention: Brief supportive‐expressive group psychotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 124
Study: 11052282

Group type: EXPERIMENTAL
Intervention: TachoComb H (haemostyptic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compresses (control)
Number of subjects: 30
Study: 9231199

Group type: EXPERIMENTAL
Intervention: 100 mg of DEC
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 8330600

Group type: EXPERIMENTAL
Intervention: subarachnoid bupivacaine plus epidural morphine and bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: subarachnoid bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: subarachnoid bupivacaine plus intravenous midazolam and buprenorphine
Number of subjects: 200

Group type: COMPARATOR
Intervention: epidural bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: epidural bupivacaine plus epidural morphine
Number of subjects: 200
Study: 3033040

Group type: EXPERIMENTAL
Intervention: Local antimicrobial prophylaxis (50 mg of polymyxin B, 80 mg of gentamicin, 300 mg of amphotericin B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 39
Study: 30145098

Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine
Number of subjects: 47366

Group type: COMPARATOR
Intervention: Hepatitis vaccines
Number of subjects: 47366
Study: 25986159

Group type: EXPERIMENTAL
Intervention: Formulated honey (53.5 g daily for 40 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non-formulated kanuka honey)
Number of subjects: 12
Study: 25509258

Group type: EXPERIMENTAL
Intervention: Compound Qizhu Granule (CQG) plus Lamivudin (LAM) and Adefovir (ADV)
Number of subjects: 103
Study: 22287641

Group type: EXPERIMENTAL
Intervention: Early passive motion exercises conducted 3 to 4 times per day during the abduction brace‐wearing period.
Number of subjects: 105

Group type: COMPARATOR
Intervention: No passive motion allowed during the same period.
Number of subjects: 105
Study: 20356588

Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excision
Number of subjects: 0
Study: 18257772

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 54
Study: 16178481

Group type: EXPERIMENTAL
Intervention: 2% mupirocin cream applied daily to the exit site
Number of subjects: 40

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 40
Study: 12955869

Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation (HFES) at 50 Hz, 15 s on, 45 s off, intensity 100 mA
Number of subjects: 7
Study: 10812753

Group type: EXPERIMENTAL
Intervention: Foot-bath with essential oil of lavender
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot-bath without essential oil of lavender
Number of subjects: 0
Study: 8853261

Group type: EXPERIMENTAL
Intervention: Pancrease HL (25,000 units of lipase per capsule, 3 capsules/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Creon (8000 units of lipase per capsule, 9 capsules/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pancrease HL with omeprazole (20 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Creon with omeprazole (20 mg/day)
Number of subjects: 25
Study: 1737543

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Insulin dose minimization
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: HLA-DR3 and -DR4 status
Number of subjects: 95
Study: 6439298

Group type: EXPERIMENTAL
Intervention: Scheduled medically and socially preventive intervention (home visits every three months)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (no scheduled intervention, visited during the final three months)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Scheduled medically and socially preventive intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study: 30920584

Group type: COMPARATOR
Intervention: Intra-procedural only bivalirudin infusion
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Prolonged bivalirudin infusion
Number of subjects: 137
Study: 30244844

Group type: EXPERIMENTAL
Intervention: Canakinumab (50mg, 150mg, or 300mg subcutaneously)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27283364

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 500 mg/day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 24670120

Group type: EXPERIMENTAL
Intervention: CHO-PROT beverage given 30 and 5 min prior to, at the 15 min mark during, immediately after, and 30 min after downhill running (360 kilocalories total in T1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO-PROT beverage given immediately after and 30 min after downhill running (isocaloric amount in T2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo beverage given at all time points
Number of subjects: 9
Study: 22278391

Group type: EXPERIMENTAL
Intervention: Trained handcyclists
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trained handcyclists at 50 W
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trained handcyclists at 80 W
Number of subjects: 20
Study: 18835953

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (n = 19,326)
Number of subjects: 38716

Group type: COMPARATOR
Intervention: Placebo (n = 19,390)
Number of subjects: 38716
Study: 17786067

Group type: EXPERIMENTAL
Intervention: Nebivolol 1.25, 2.5, 5, 10, 20, or 40 mg once daily for up to 84 days
Number of subjects: 909

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 909
Study: 14638340

Group type: EXPERIMENTAL
Intervention: Triple therapy regimen including amoxicillin and clarithromycin with omeprazole, lansoprazole, or rabeprazole
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers in normal acid secretion IL-1beta genotype group
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CYP2C19 homozygous in normal acid secretion IL-1beta genotype group
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CYP2C19 heterozygous in normal acid secretion IL-1beta genotype group
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low acid secretion IL-1beta genotype group
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype status
Number of subjects: 249
Study: 10826574

Group type: EXPERIMENTAL
Intervention: Transcervical intrauterine instillation of 5 mL of 2% lignocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90